| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/neuroimage/JoshiKF09 |
| P356 | DOI | 10.1016/J.NEUROIMAGE.2009.01.057 |
| P932 | PMC publication ID | 4308413 |
| P698 | PubMed publication ID | 19457369 |
| P5875 | ResearchGate publication ID | 24441602 |
| P50 | author | Jeffrey A Fessler | Q39570154 |
| P2093 | author name string | Robert A Koeppe | |
| Aniket Joshi | |||
| P2860 | cites work | AIDA: an adaptive image deconvolution algorithm with application to multi-frame and three-dimensional data | Q33284201 |
| A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). | Q36887715 | ||
| Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. | Q48108810 | ||
| Anatomic standardization: linear scaling and nonlinear warping of functional brain images. | Q52371563 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 154-159 | |
| P577 | publication date | 2009-02-06 | |
| P1433 | published in | NeuroImage | Q1981225 |
| P1476 | title | Reducing between scanner differences in multi-center PET studies | |
| P478 | volume | 46 |
| Q30971403 | 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception |
| Q37184305 | Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment |
| Q36943464 | Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals |
| Q50547223 | Amyloid-independent functional neural correlates of episodic memory in amnestic mild cognitive impairment. |
| Q37106026 | Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods |
| Q37973222 | Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents |
| Q37129672 | Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people |
| Q37623183 | Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. |
| Q64084604 | Cognitive Profiling Related to Cerebral Amyloid Beta Burden Using Machine Learning Approaches |
| Q37107044 | Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid |
| Q33604453 | Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database |
| Q64109135 | Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies |
| Q38739937 | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| Q38692086 | Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements |
| Q50972863 | Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. |
| Q48507772 | Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). |
| Q42328545 | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| Q34730215 | FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease |
| Q99603509 | High pulse pressure is a risk factor for prodromal Alzheimer's disease: a longitudinal study |
| Q38683683 | Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology |
| Q38384827 | Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care? |
| Q42235617 | Impact of MR-Based Attenuation Correction on Neurologic PET Studies. |
| Q47128927 | Impact of Time-of-Flight and Point-Spread-Function for Respiratory Artifact Reduction in PET/CT Imaging: Focus on Standardized Uptake Value |
| Q51744764 | Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment. |
| Q51703164 | Modulation of glucose metabolism and metabolic connectivity by β-amyloid. |
| Q37957134 | Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies |
| Q37662208 | Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. |
| Q58765546 | Multicentre analysis of PET SUV using vendor-neutral software: the Japanese Harmonization Technology (J-Hart) study |
| Q38576124 | Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection |
| Q33605578 | Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults |
| Q34448672 | Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow |
| Q41140682 | Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease |
| Q93242548 | Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers |
| Q30419180 | Nuclear imaging of the breast: translating achievements in instrumentation into clinical use |
| Q33834876 | Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study |
| Q35222298 | Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals |
| Q39859165 | Optimization of brain PET imaging for a multicentre trial: the French CATI experience |
| Q51784613 | Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging. |
| Q47905334 | Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. |
| Q89803961 | PET image super-resolution using generative adversarial networks |
| Q41716835 | Partial volume correction in quantitative amyloid imaging |
| Q48162000 | Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET. |
| Q42690171 | Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. |
| Q37314035 | Phantom criteria for qualification of brain FDG and amyloid PET across different cameras. |
| Q34955852 | Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging Study |
| Q28545789 | Quantitative amyloid imaging using image-derived arterial input function |
| Q30835467 | Quantitative assessment of rest and acetazolamide CBF using quantitative SPECT reconstruction and sequential administration of (123)I-iodoamphetamine: comparison among data acquired at three institutions |
| Q59844929 | Quantitative evaluation of tau PET tracers F-THK5351 and F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization |
| Q48628422 | Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner |
| Q36451170 | Random forest-based similarity measures for multi-modal classification of Alzheimer's disease |
| Q37344722 | Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects |
| Q30557788 | Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease |
| Q35650639 | SUVref: reducing reconstruction-dependent variation in PET SUV. |
| Q58092575 | Secondary prevention of Alzheimer's dementia: neuroimaging contributions |
| Q38601642 | Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging |
| Q49351656 | Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study |
| Q91655785 | Spatially Distributed Amyloid-β Reduces Glucose Metabolism in Mild Cognitive Impairment |
| Q92221490 | Tau and atrophy: domain-specific relationships with cognition |
| Q39430101 | Technical Note: Development of a 3D printed subresolution sandwich phantom for validation of brain SPECT analysis |
| Q34061794 | The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core |
| Q27006831 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception |
| Q34065449 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. |
| Q34296479 | The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging |
| Q28749583 | The informatics core of the Alzheimer's Disease Neuroimaging Initiative |
| Q34674417 | The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function |
| Q34421586 | Three-dimensional brain phantom containing bone and grey matter structures with a realistic head contour. |
| Q48547494 | Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis |
| Q47118607 | Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants |
| Q90406450 | Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies |
| Q36243629 | Validation of 18F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners |
| Q47547648 | [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. |
Search more.